felodipine has been researched along with Hypercholesterolemia in 3 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 9.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 5.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wassmann, S | 1 |
| Hilgers, S | 1 |
| Laufs, U | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| O'Callaghan, CJ | 1 |
| Krum, H | 1 |
| Conway, EL | 1 |
| Lam, W | 1 |
| Skiba, MA | 1 |
| Howes, LG | 1 |
| Louis, WJ | 1 |
| Wang, BY | 1 |
| Niebauer, J | 1 |
| Singer, AH | 1 |
| Tsao, PS | 1 |
| Cooke, JP | 1 |
2 trials available for felodipine and Hypercholesterolemia
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biomarker | 2002 |
Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.
Topics: Blood Pressure; Captopril; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Me | 1994 |
1 other study available for felodipine and Hypercholesterolemia
| Article | Year |
|---|---|
Felodipine inhibits intimal lesion formation in the hypercholesterolemic rabbit: differential effects on endothelial and monocyte determinants of atherogenesis.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Calcium Channel Blockers; Cell Adhesion; | 1996 |